An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
Latest Information Update: 13 Nov 2024
Price :
$35 *
At a glance
- Drugs Vutrisiran (Primary)
- Indications Amyloidosis
- Focus Adverse reactions; Registrational
- Sponsors Alnylam Pharmaceuticals
- 13 Nov 2024 New trial record